GSK Investigational Site

Copenhagen DK-2100

3 studies enrolling now · 24 studies all time

What they study most

Arthritis, Rheumatoid, Asthma, Chickenpox, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Fibrolamellar Carcinoma, Glioblastoma Multiforme (GBM), HIV Infection, HIV Infections, Hepatic Tumors

Studies at this site

• A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors — Recruiting now
• A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) — Recruiting now
• A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age — Recruiting now
• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Running, not enrolling
• A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Running, not enrolling
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer — Running, not enrolling
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer — Running, not enrolling
• Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA) — Completed
• A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) — Completed
• A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) — Completed
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 — Stopped early
• GW873140 In Combination With Kaletra In HIV Infected Subjects — Stopped early
• Thiazolidinedione Intervention With Vitamin D Evaluation — Stopped early
• Post-Operative Nausea And Vomiting Study In Female Patients — Completed
• Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 — Stopped early